X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

SAN FRANCISCO-Pfizer may have a sublease tenant for its 105,000-square-foot leasehold in Mission Bay. Pfizer CEO Joel Marcus said as much earlier this month during a conference call with analysts and Mayor Gavin Newsom reiterated it earlier this week, hinting during a speech at the Mission Bay Conference Center that a new biotech-related tenant is about to announce plans to assume the long-term lease Pfizer signed this time last year and last month said it would never occupy.

It makes no difference to Alexandria Real Estate Equities, the owner and developer of the building. Pfizer CEO Joel Marcus told analysts last week that Pfizer signed a 15-year lease that provides no “outs” until year 10. “They are looking to sublease and we understand they may be very close to achieving their goal, but we still have Pfizer cash and Pfizer credit on the lease for a 10 year period,” Marcus said.

Pfizer’s Biotherapeutics and Bioinnovation Center was scheduled to occupy the upper west-wing floors of 455 Mission Bay in early 2010, which is when it is scheduled for completion. The company reportedly held an option to lease an additional 50,000-square-foot in the east wing. Those plans changed abruptly after it acquired Madison, NJ-based Wyeth Pharmaceuticals earlier this year

A Pfizer spokeswoman told GlobeSt.com in July that the global real estate portfolio that comes with Wyeth played into the company’s decision not to relocate its biotheraputics research operation to Mission Bay. Also taken into account were overall occupancy costs and the disruption to science caused by the relocation of a research operation, she said.

As a result, Pfizer’s existing biotheraputics research operation will remain in South San Francisco at 259 East Grand Ave., the home of Rinat Neuroscience, a company it acquired in 2006, and the man slated to head the new center, Bay Area biotech entrepreneur Corey Goodman, is no longer with the company.

Pfizer leasehold is in 455 Mission Bay. Pfizer’s Biotherapeutics and Bioinnovation Center was scheduled to occupy the upper west-wing floors of 455 Mission Bay in early 2010, which is when it is scheduled for completion. Pfizer’s potential subtenant is “something arguably much better than Pfizer,” Newsom said at the conference center, declining to elaborate.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?

GlobeSt

Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.